Polyclonal Antibody Sequencing Services2021-10-15T10:05:47-04:00

Antibody Discovery via Polyclonal Antibody Sequencing.

Our REpAb® platform is the next generation of species agnostic antibody discovery that sequences antibody proteins directly from blood or a polyclonal mixture.

Advantages with REpAb® Polyclonal Antibody Sequencing.

Advantages with REpAb® Polyclonal Antibody Sequencing.

Access Circulating mAbs Directly

Antibodies found in serum by REpAb® represent the most abundant antibodies that bind to the target of interest. Only REpAb can access functional native molecules.

Convert pAb into Recombinant mAbs

This both reduces the use of animals and increases the production scale and reproducibility of your antibody products through recombinant expression.

Discover a Diverse Collection of mAbs

A series of mAbs purified against sub-domains of the protein antigen can recapitulate biophysical diversity of the native immune response.

Turn Polyclonal Antibodies into rAbs.

Polyclonal antibodies (pAb) are extensively used to address challenging targets. But, they suffer from batch-to-batch variability, require culling many animals, and are notoriously difficult to characterize, limiting their use. With REpAb®, a pAb mixture can be sequenced to secure robust mAb clones for recombinant antibody (rAb) expression and recapitulate the polyclonal response.

Species Agnostic Discovery.

Unlike other monoclonal antibody discovery platforms, REpAb® does not rely on a single animal model. REpAb® exploits de novo protein sequencing, which means that REpAb® is agnostic to the host organism. This feature enables mAb discovery in any species from which an antigen-specific IgG fraction from non-pooled single donors can be obtained, be it rabbit, dog, goat, mice, human, or others.

A Complementary Approach.

Hybridoma, display libraries and single-cell sequencing are established techniques, but are often a poor snapshot of the real antibody repertoire in circulation. REpAb® can extract vital biophysical information such as PTMs, as well as confirm the protein sequence to complement existing pipelines while contributing more robust, and more easily characterized mAb candidates.

How REpAb® Antibody Discovery Works.

How REpAb® Antibody Discovery Works.

The REpAb® approach can sequence and express mAbs directly from a polyclonal mixture isolated from a single donor – a Rapid Novor first. Genomic information can be added to the workflow if available. REpAb® can start with either a pAb mixture of interest, a new immunization or the blood of your immunized animal. The work results in mAb sequences that are then used to recombinantly express a number of distinct antibodies that bind to the original antigen (optionally, your team can conduct the recombinant expression step). Binding is confirmed prior to delivery.

The REpAb® approach can sequence and express mAbs directly from a polyclonal mixture isolated from a single donor – a Rapid Novor first. Genomic information can be added to the workflow if available. REpAb® can start with either a pAb mixture of interest, a new immunization or the blood of your immunized animal. The work results in mAb sequences that are then used to recombinantly express a number of distinct antibodies that bind to the original antigen (optionally, your team can conduct the recombinant expression step). Binding is confirmed prior to delivery.

“Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target- and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet the Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands.”
Matt Pope, VP of Client Services, SISCAPPA

A World’s First: De Novo Polyclonal Antibody Sequencing.

Rapid Novor is the first and only team to successfully sequence pAbs using mass spectrometry, and without reference to nucleotide sequences. The recombinant antibodies made from the sequenced pAbs have affinity comparable if not better than the original pAbs.

Pricing.

Pricing is tailored to your project and needs. We make it very easy to get started to ensure of the success of the whole project or future projects. Please inquire for details.

Getting Started is Easy.

In order to take advantage of our REpAb® service, you must have:

  1. 1mg of antigen affinity purified polyclonal antibody. Providing 3-5 ml of blood is an option if available to you. OR…
  2. the antigen or information about your target of interest (if we are performing the immunization step)

Deliverables can include the full mAb sequences with heavy and light chains properly paired, CDR clusters, NGS data, recombinantly expressed antibodies and antigen binding results (depending on the options you select).

Learn More.

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

DNA Sequencing vs Next Generation Protein Sequencing

The protein sequence is key to understanding the function of a protein target, and is critical to therapeutic and diagnostic development. This is particularly important for antibodies whose code diversity and glycosylation impact both function, and stability.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 3000 antibodies and we are eager to help you.